arginyl-glycyl-aspartic acid has been researched along with Sarcoma 180 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, G; Li, X; Li, Y; Ren, Z; Sun, Y; Zheng, X | 1 |
| Cui, C; Cui, G; Liu, H; Ren, Z; Wang, F; Wang, L | 1 |
2 other study(ies) available for arginyl-glycyl-aspartic acid and Sarcoma 180
| Article | Year |
|---|---|
RGD-fatty alcohol-modified docetaxel liposomes improve tumor selectivity in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Docetaxel; Drug Delivery Systems; Fatty Alcohols; Humans; Injections, Intravenous; Liposomes; Liver; Male; Mice, Inbred ICR; Models, Biological; Oligopeptides; Sarcoma 180; Taxoids; Technology, Pharmaceutical; Tissue Distribution; Tumor Burden | 2014 |
Preparation and biological evaluation of tumor-specific Ara-C liposomal preparations containing RGDV motif.
Topics: Animals; Antimetabolites, Antineoplastic; Cytarabine; Drug Delivery Systems; Liposomes; Male; Mice; Oligopeptides; Sarcoma 180 | 2012 |